Table 1.
Summary of baseline demographic and disease-related characteristics, mITT population.
| Nitazoxanide (N = 184) | Placebo (N = 195) | All mITT Participants (N = 379) | |
|---|---|---|---|
| Male, N (%) | 83 (45·1%) | 82 (42·1%) | 165 (43·5%) |
| Median (Range) Age (years) | 38 (12–83) | 42 (13–81) | 40 (12–83) |
| Race or Ethnic Group, N (%) | |||
| White | 117 (63·6%) | 116 (59·5%) | 233 (61·5%) |
| Hispanic or Latino | 59 (32·1%) | 71 (36·4%) | 130 (34·3%) |
| Black or African American | 4 (2·2%) | 4 (2·1%) | 8 (2·1%) |
| Asian | 2 (1·1%) | 4 (2·1%) | 6 (1·6%) |
| Other | 2 (1·1%) | 0 (0·0%) | 2 (0·5%) |
| Median (IQR) BMI | 28·7 (25·3, 33·5) | 29·1 (25·7, 33·6) | 28·9 (25·5, 33·5) |
| Median Hours Since Onset of Symptoms | 43·9 | 46·5 | 45·9 |
| Moderate Disease Severity, N (%) | 68 (37·0%) | 65 (33·3%) | 133 (35·2%) |
| At Risk of Severe Illness per CDC Guidelines, N (%) | 112 (60·9%) | 126 (64·6%) | 238 (62·8%) |
| Viral Load, log10 RNA copies/mL | |||
| Median (IQR) | 6·38 (4·71, 7·401) | 6·34 (4·40, 7·401) | 6·36 (4·62, 7·401) |
| SARS-CoV-2 Antibody-Positive, N (%) | 18 (4·7%) | 20 (5·3%) | 38 (10·0%) |
1
7.40 log10 copies/mL is the upper limit of quantitation of the assay.